Research trends of platelet-rich plasma application in orthopaedics from 2002 to 2020: a bibliometric analysis

Ren, Bolin; Lv, Xin; Tu, Chao; Li, Zhihong

doi:10.1007/s00264-021-05163-6

Cited by 19 publications

(20 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PRP is obtained by collecting peripheral blood and processing it by centrifugation (usually 5 min at 1500 rpm). It contains platelets, growth factors, white blood cells, and red blood cells [3,7,10,11,29,37]. Growth factors which promote cartilage healing are transforming growth factor (TGFB-1), insulin like growth factor (IGF-1), fibroblast growth factor (bFGF), and bone morphogenic proteins (BMP-2).…”

Section: Intraarticular Injectionsmentioning

confidence: 99%

“…Growth factors which promote cartilage healing are transforming growth factor (TGFB-1), insulin like growth factor (IGF-1), fibroblast growth factor (bFGF), and bone morphogenic proteins (BMP-2). Those which deter are, among others, vascular epithelial growth factor (VEGF), insulin like growth factor binding protein (IGFBP-2 and 3), platelet derived growth factor PDGF-AA, AB, and BB, and endothelial growth factor (EGF) [3,7,10,11,29,37]. PRPs can be leucocyte rich (pro inflammatory, used for tendinitis) or poor (anti-inflammatory) which have better results in OA with an inflammatory component (morning stiffness, effusion with physical activity) [3,7,10,11,29,37].…”

Section: Intraarticular Injectionsmentioning

confidence: 99%

“…Those which deter are, among others, vascular epithelial growth factor (VEGF), insulin like growth factor binding protein (IGFBP-2 and 3), platelet derived growth factor PDGF-AA, AB, and BB, and endothelial growth factor (EGF) [3,7,10,11,29,37]. PRPs can be leucocyte rich (pro inflammatory, used for tendinitis) or poor (anti-inflammatory) which have better results in OA with an inflammatory component (morning stiffness, effusion with physical activity) [3,7,10,11,29,37]. Currently there are many products on the market, all of which differ regarding centrifugation parameters, platelet and white cells count, and growth factor concentration.…”

Section: Intraarticular Injectionsmentioning

confidence: 99%

“…The efficacy of PRP remains controversial. The major issues are come from the experimental methods, confusing nomenclature, non standardized preparation methods and lack of in-depth understanding of mechanisms of action [37].…”

Section: Intraarticular Injectionsmentioning

confidence: 99%

See 3 more Smart Citations

Potential New Treatments for Knee OA: A Prospective Review of Registered Trials

et al. 2021

View full text Add to dashboard Cite

We aimed to evaluate potential new treatments for knee osteoarthritis (OA). The National Institute of Health ClinicalTrials.gov database was searched for “Osteoarthritis, Knee”. We found 565 ongoing interventional studies with a total planned enrollment of 111,276 subjects. Ongoing studies for knee OA represent a very small fraction of the registered clinical trials, but they are over a quarter of all knee trials and over two thirds of all OA studies. The most researched topic was arthroplasty, with aspects such as implant design changes, cementless fixation, robotic guidance, pain management, and fast track recovery. Intraarticular injections focused on cell therapies with mesenchymal stem cells sourced from adipose tissue, bone marrow, or umbilical cord. We could see the introduction of the first disease modifying drugs with an impact on knee OA, as well as new procedures such as geniculate artery embolization and geniculate nerve ablation.

show abstract

Section: Intraarticular Injectionsmentioning

confidence: 99%

Section: Intraarticular Injectionsmentioning

confidence: 99%

Section: Intraarticular Injectionsmentioning

confidence: 99%

Section: Intraarticular Injectionsmentioning

confidence: 99%

See 2 more Smart Citations

Potential New Treatments for Knee OA: A Prospective Review of Registered Trials

et al. 2021

View full text Add to dashboard Cite

show abstract

“…6,7) Platelet-rich plasma (PRP), an autologous derivative of the whole blood, has a higher platelet count than that of peripheral blood. 8) Several studies have demonstrated that the proliferative and synthesizing capacities of BMSCs are enhanced by PRP. [9][10][11] The administration of PRP could not only boost the formation of cartilage repair tissue but also could attain the quality of the level of native tissue.…”

Section: Introductionmentioning

confidence: 99%

Berberine Encapsulated in Exosomes Derived from Platelet-Rich Plasma Promotes Chondrogenic Differentiation of the Bone Marrow Mesenchymal Stem Cells <i>via</i> the Wnt/β-Catenin Pathway

Dong

Liu

et al. 2022

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Cartilage regenerative medicine, wherein the stem cells from adults exert a crucial role, has high potential in the treatment of defective articular cartilage. Recently, Bone marrow mesenchymal stem cells (BMSCs) are being increasingly recognized as an alternative source of adult stem cells, which are capable of differentiating into several cell types (e.g., adipocytes, chondrocytes, and osteoblasts). However, their proliferative properties and tendency to dedifferentiate restrict their use in clinical settings. Recently, a possible bioactive material PRP-exos (exosomes derived from platelet-rich plasma), has emerged, which can effectively facilitate the differentiation and proliferation of cells. Recent studies have reported that berberine (Ber), known to have antiinflammatory properties, plays a role in osteogenesis. Since biological molecules are used in combinations, we attempted to assess the effect of Exos-Ber (PRP-exos in combination with Ber) on the chondrogenic differentiation of BMSCs in vitro. In this study, Exos-Ber was observed to promote the proliferation of BMSCs and cause their chondrogenic differentiation in vitro. Additionally, Exos-Ber could promote the migration of BMSCs and increase the protein expression of the chondrogenic genes (Collagen II, SOX9, Aggrecan). After treatment with Exos-Ber, significant induction of β-catenin expression was observed, which could be repressed successfully by adding β-catenin inhibitor XAV-939. Interestingly, the repression of the Wnt/β-catenin axis also resulted in reduced gene expression levels of Collagen II, SOX9, and Aggrecan.These observations indicated that Exos-Ber facilitated the differentiation of chondrogenic BMSCs by modulating the Wnt/β-catenin axis, which offers innovative insights into the reconstruction of cartilage.

show abstract

The editor endeavours, aims and standards in a surgery journal: our experience with “International Orthopaedics” and the Société Internationale de Chirurgie Orthopédique et de Traumatologie publications

Mavrogenis

Scarlat

2022

International Orthopaedics (SICOT)

View full text Add to dashboard Cite

Research trends of platelet-rich plasma application in orthopaedics from 2002 to 2020: a bibliometric analysis

Cited by 19 publications

References 50 publications

Potential New Treatments for Knee OA: A Prospective Review of Registered Trials

Potential New Treatments for Knee OA: A Prospective Review of Registered Trials

Berberine Encapsulated in Exosomes Derived from Platelet-Rich Plasma Promotes Chondrogenic Differentiation of the Bone Marrow Mesenchymal Stem Cells <i>via</i> the Wnt/β-Catenin Pathway

The editor endeavours, aims and standards in a surgery journal: our experience with “International Orthopaedics” and the Société Internationale de Chirurgie Orthopédique et de Traumatologie publications

Contact Info

Product

Resources

About